The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessAbstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 301–400 of 806
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
Considerations for treatment of lipid disorders during pregnancy and breastfeeding
Kaur, G., & Gulati, M. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.001 · Cited by 17
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 19
“Moreover, ATP citrate lyase downregulation and AMP-activated protein kinase (AMPK) upregulation improves glucose metabolism regulation [60] and reduces the inflammatory pathway and cytokine production [72] The safety and efficacy of the long-term use of bempedoic acid have been investigated in several clinical trials,…”
MethodMormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 19
“…Tranquility (in statin-intolerant patients) [71]; (2) CLEAR Harmony (patients with LDL-C ≥ 70 mg/dL despite maximally tolerated statin therapy) [72]; (3) CLEAR Wisdom (patients with ASCVD, HeFH, or both, on optimal statin treatment) [73]; and (4) CLEAR Serenity (statin-intolerant patients with…”
BackgroundPapafaklis, M. I., Koros, R., Tsigkas, G., Καρανάσος, Α., Μούλιας, Α., & Davlouros, P. A. (2024) · Biomedicines · doi:10.3390/biomedicines12112435 · Cited by 19
“Clinical trials have tested its use both as monotherapy and as complementary therapy in patients who do not reach their target goals (LDL > 70 mg/dL) on a maximally tolerated statin dose with or without additional lipid-lowering agents [108,109].”
ACLY-matizing Macrophages to Histone Modification during Immunometabolic Reprogramming
Williams, N. C., & O'Neill, L. A. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2019.12.009 · Cited by 14
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
Kayki‐Mutlu, G., & Michel, M. C. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02085-3 · Cited by 15
“Patients receiving bempedoic acid were shown to have lowered LDL-C levels along with the lowered non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high sensitivity C-reactive protein (Goldberg et al. 2019; Ray et al. 2019; Banach et al. 2020).”
BackgroundZhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
“The trial found that bempedoic acid significantly reduced LDL-C level with an overall safety profile similar to that of placebo but bempedoic acid was associated with increased incidence of gout and discontinuation of the regimen due to reported adverse events.(65) Bempedoic acid has been approved by FDA as an adjunct…”
BackgroundGaine, S. P., Quispe, R., Patel, J., & Michos, E. D. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00694-y · Cited by 15
Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice
Bradley, C., Kolkailah, A. A., Shah, N. P., Page, C. B., Peterson, E. D., & Návar, A. M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.006 · Cited by 15
Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance
Susekov, A. V., Король, Л. А., & Watts, G. F. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07139-x · Cited by 13
“To date, the lipid-lowering efficacy of ET-1002 has been well investigated in phase III studies, including CLEAR Tranquility [42], CLEAR Serenity [43], CLEAR Harmony [44], and CLEARWisdom [45] (Table 2).”
BackgroundMethodInfluentialStatin intolerance: myths and facts
Laufs, U., & Isermann, B. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa582 · Cited by 14
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
“It acts on the cholesterol synthesis pathway, inhibiting cholesterol synthesis, and was demonstrated to lower LDL-C by approximately 23% in monotherapy, 18% when administered as a background of statin therapy, and 38% when combined with ezetimibe [142,143] [Table 2].”
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
van den Bosch, S. E., Corpeleijn, W. E., Hutten, B. A., & Wiegman, A. (2023) · Genes · doi:10.3390/genes14030669 · Cited by 17
Traditional and novel non-statin lipid-lowering drugs
Jain, P. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.003 · Cited by 16
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Gowda, D., Shekhar, C., Gowda, S. G. B., Chen, Y., & Hui, S. (2023) · Livers · doi:10.3390/livers3040045 · Cited by 15
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
Yarrarapu, S. N. S., Goyal, A., Venkata, V. S., Panchal, V. S., Sivasubramanian, B. P., Du, D. T., Jakulla, R. S., Pamulapati, H., Afaq, M. A., Owens, S., et al. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.03.006 · Cited by 15
Butera, E., Termite, F., Esposto, G., Galasso, L., Mignini, I., Borriello, R., Ainora, M. E., Miele, L., Gasbarrini, A., & Zocco, M. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136938 · Cited by 15
“Bempedoic acid was approved by the FDA for reducing LDL-C in February 2020 [69], and the EMA recommended approval in January 2020 [70].”
MethodThe Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, W. Z., & Yee, J. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01013-x · Cited by 13
Gunn, L. H., McKay, A. J., Feng, A., Louie, M. J., Ballantyne, C. M., & Ray, K. K. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.003 · Cited by 14
“Cohort 1 comprised patients enrolled in the CLEAR Harmony and CLEAR Wisdom studies who had baseline LDL-C levels 70 mg/dL and 100 mg/dL, respectively, despite taking maximally tolerated statins [12,13].”
MethodSelf-citationNational Institute for Health and Care Excellence guidelines for lipid management
Cegla, J. (2022) · Heart · doi:10.1136/heartjnl-2022-321414 · Cited by 16
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
“44 47 It is an effective oral adjunct to ezetimibe in statin-intolerant patients.”
BackgroundBempedoic acid: new evidence and recommendations on use
Paponja, K., Pećin, I., Reiner, Ž., & Banach, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000911 · Cited by 16
An Update on Dyslipidemia Management and Medications: A Review
Taher, Z. A., Taher, A. A., & Radi, S. (2024) · Cureus · doi:10.7759/cureus.56255 · Cited by 21
Zhao, Z., Wan, J., Chen, H., Sun, Z.-S., Tao, Y.-T., Tong, Y., Zang, Y., Choo, Y., Wang, P., Li, Y., et al. (2024) · Phytochemistry · doi:10.1016/j.phytochem.2024.114259 · Cited by 12
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Almendra‐Pegueros, R., Camacho, M., Rodríguez‐Sinovas, A., Galán, M., Roglans, N., Laguna, J. C., Martínez‐González, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117876 · Cited by 12
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Linden, K., Mailey, J. A., Kearney, A., & Menown, I. B. A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01355-5 · Cited by 13
“In the CLEAR Harmony study 2230 patients with high CV risk and on maximally tolerated statins were randomised (2:1) to bempedoic acid or placebo [54].”
BackgroundMethodGencer, B., & Giugliano, R. P. (2020) · Clinical Cardiology · doi:10.1002/clc.23410 · Cited by 15
“Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) study (evolocumab vs standard care).(10,21) The guidelines have many similarities.”
BackgroundCorpeleijn, W. E., de Waal, W. J., Schipper, H. S., & Wiegman, A. (2023) · Diabetologia · doi:10.1007/s00125-023-06041-z · Cited by 16
“In recent years, several new types of drugs that regulate LDL-c levels, such as bempedoic acid and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [44–46], have become available.”
BackgroundThe Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
“EPA is mostly studied and described to inhibit inflammation, cholesterol crystal formation, to reduce oxidative properties of atherogenic lipoproteins and to increase plaque instability (reviewed in References [88,89]).”
BackgroundAgboola, F., Lin, G. A., Kazi, D. S., McKenna, A., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.961 · Cited by 12
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Bempedoic acid and ezetimibe – better together
Khan, S. U., & Michos, E. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864672 · Cited by 13
“In the CLEAR Harmony trial (n1⁄4 2230), bempedoic acid reduced LDL-C levels by 18% at 12 weeks.(9) Similarly, the CLEAR WISDOM trial (n1⁄4 779) presented at the 2019 American College of Cardiology (ACC) meeting, showed a 15.”
BackgroundResultInfluentialBenefits of Bempedoic Acid — Clearer Now
Alexander, J. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2301490 · Cited by 12
Katamine, M., Minami, Y., & Ako, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22044 · Cited by 19
“Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers the low-density lipoprotein cholesterol (LDL-C) levels by targeting cholesterol synthesis upstream of HMG-CoA reductase 64) .”
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 13
“…in combination with statins or ezetimibe (or triple combination), making it a particularly effective alternative for statin-intolerant patients, 171,172 as shown by the CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen) Outcomes trial which showed a 13.3%…”
InfluentialMcQueen, R. B., Baum, S. J., Louie, M. J., Sasiela, W. J., Bilitou, A., Shah, H., Nash, B., Gillard, K. K., & Ray, K. K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00552-7 · Cited by 15
“3% discontinuation rate was applied for the first year and a 2% discontinuation rate was assumed for each subsequent year [28].”
BackgroundSelf-citationAllosteric role of the citrate synthase homology domain of ATP citrate lyase
Wei, X., Schultz, K. C., Pepper, H. L., Megill, E., Vogt, A. D., Snyder, N. W., & Marmorstein, R. (2023) · Nature Communications · doi:10.1038/s41467-023-37986-9 · Cited by 12
Katzmann, J. L., Stürzebecher, P. E., Kruppert, S., & Laufs, U. (2024) · Scientific Reports · doi:10.1038/s41598-023-50847-1 · Cited by 13
Biju, A. K., Lakshmikumar, R. R. C., & Rengasamy, K. R. R. (2024) · Natural Resources for Human Health · doi:10.53365/nrfhh/189500 · Cited by 11
“The findings revealed no notable distinction in adverse events between the two groups (Ray et al., 2019).”
BackgroundLipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 13
Agha, A. M., Jones, P. H., Ballantyne, C. M., Virani, S. S., & Nambi, V. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.07.002 · Cited by 13
Self-citationMehta, V., Puri, R., Duell, P. B., Iyengar, S. S., Wong, N. D., Yusuf, J., Mukhopadhyay, S., Pradhan, A., Muruganathan, A., WANGNOO, S. K., et al. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0099 · Cited by 16
Goldberg, A. C., Banach, M., Catapano, A. L., Duell, P. B., Leiter, L. A., Hanselman, J. C., Lei, L., & Mancini, G. B. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117192 · Cited by 15
“Clinical laboratory samples were collected up to week 52 in CLEAR Wisdom and CLEAR Harmony, and up to week 24 and week 12 for CLEAR Serenity and CLEAR Tranquility, respectively [16 – 19].”
BackgroundMethodInfluentialSelf-citationLiang, K., Wang, Q., Qiu, L., Gong, X., Chen, Z., Zhang, H., Ding, K., Liu, Y., Wei, J., Lin, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115658 · Cited by 13
“The data generated in clinical settings with respect to ACLY inhibition lowered the established LDL safely and effectively [101,102].”
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
Meta-analysis of the Safety and Efficacy of Bempedoic Acid
Khan, M. U., Khan, M. Z., Munir, M. B., Balla, S., & Khan, S. U. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.028 · Cited by 14
Role of Bempedoic Acid in Dyslipidemia Management
Kelly, M. S., Sulaica, E. M., & Beavers, C. J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000887 · Cited by 11
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Xu, Y., Lu, J., Guo, Y., Zhang, Y., Liu, J., Huang, S., Zhang, Y., Gao, L., & Wang, X. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.05.009 · Cited by 13
Araújo, B., Arrighini, G. S., Queiroga, F., Mansouri, E. S., Rivera, A., Amador, W. F. O., Queiroz, I., Akabane, M. A. C. C., Consoli, L. N., Sobral, M. V. S., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101303 · Cited by 10
“Bempedoic acid reduces LDL-C by 24 % when used alone and 18 % when added to a statin [24,25].”
Raposeiras‐Roubín, S., Assi, E. A., Jiménez-Méndez, C., de la Guía, E. M., Pérez-Rivera, J.-Á., Mangas, M. M., Ayesta, A., Uribarri, A., Jorge‐Pérez, P., Muiños, P. J. A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075388 · Cited by 13
Faggiano, A., Maloberti, A., Ambrosetti, M., Giallauria, F., Mureddu, G., Venturini, E., Ruzzolini, M., Maranta, F., Vatri, M., Zadre, L., et al. (2026) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.11.010 · Cited by 10
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
“Patients with ASCVD or FeFH who are receiving maximally tolerated statins treatment benefited with additional BDA treatment by 19.2 mg/dL reduction of the mean LDL-C level from base-line in the CLEAR Harmony trial [98].”
InfluentialMarazzi, G., Caminiti, G., Perrone, M., Campolongo, G., Cacciotti, L., Giamundo, D., Iellamo, F., Severino, P., Volterrani, M., & Rosano, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11090286 · Cited by 10
Management of dyslipidaemia in patients with comorbidities—facing the challenge
Frühwald, L., Fasching, P., Dobrev, D., Kaski, J. C., Borghi, C., Waßmann, S., Huber, K., Semb, A. G., Agewall, S., & Drexel, H. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae095 · Cited by 11
Recent Advances in the Management of Dyslipidemia: A Systematic Review
Feng, H. J. X., Yousaf, A., Moon, J., Ramiz, A., Krishma, U., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.81034 · Cited by 22
“%) in the bempedoic acid group [54].”
HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications
Stoicescu, C. I., Văcărescu, C., & Cozma, D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144945 · Cited by 17
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Jarrah, M., Ababneh, M. J., Tawalbeh, L. I., Hammoudeh, A. J., Barukba, H., & Othman, A. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.12.036 · Cited by 11
“149 management of high cholesterol and it was indicated to decrease the risk of CVD [7,8].”
BackgroundBempedoic acid: A nonstatin drug for the management of hypercholesterolemia
Govindaraju, A., & Sabarathinam, S. (2021) · Health Science Reports · doi:10.1002/hsr2.431 · Cited by 9
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Wan, S., Ding, Y., Ji, X., & Meng, R. (2021) · Aging and Disease · doi:10.14336/ad.2021.0412 · Cited by 11
“CLEAR Harmony NCT02666664 2019 [81] 103.”
Shapiro, M. D., Taub, P. R., Louie, M. J., Lei, L., & Ballantyne, C. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.973 · Cited by 12
Self-citationNonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 15
“20,21 In the recently published CLEAR Outcomes trial, 8 13,970 patients with a prior cardiovascular event or at high risk for ASCVD and unable to tolerate more than a very low dose of a statin (22.7% of patients were taking a low-dose statin and 11.5% were taking ezetimibe) were randomized to…”
BackgroundInfluentialClinical Benefit of Bempedoic Acid in Randomized Clinical Trials
Cordero, A., Olmo, R. F., Santos‐Gallego, C. G., Fácila, L., Bonanad, C., Castellano, J. M., Rodríguez‐Mañero, M., Seijas‐Amigo, J., González‐Juanatey, J. R., & Badimón, J. J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.145 · Cited by 11
Bempedoic Acid and the Prevention of Cardiovascular Disease
Keaney, J. F. (2023) · New England Journal of Medicine · doi:10.1056/nejme2300793 · Cited by 11
ACLY and CKD: A Mendelian Randomization Analysis
Mohammadi‐Shemirani, P., Chong, M., Perrot, N., Pigeyre, M., Steinberg, G. R., Paré, G., Krepinsky, J. C., & Lanktree, M. B. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.013 · Cited by 9
“50 mmol/l (18%) and did not increase the incidence of adverse events compared with placebo.(26) We observed a 0.”
Wang, P., Peng, X., Hou, T., Xu, F., Zhou, H., Yu, Y., Qiu, M., Liu, Y., Zhao, Y., Guo, Z., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110199 · Cited by 9
Toplak, H., Bilitou, A., Alber, H. F., Auer, J., Clodi, M., Ebenbichler, C. F., Fließer-Görzer, E., Gelsinger, C., Hanusch, U., Ludvik, B. H., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02221-4 · Cited by 9
Self-citationReshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Strikić, D., Begic, Z., Radman, I. B., Zlopasa, F., Mateljic, J., Zec, I., Titlić, M., Slišković, A. M., Pećin, I., Reiner, Ž., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061460 · Cited by 12
“Due to its unique molecular structure, bempedoic acid is an oral prodrug that requires hepatic activation by very long-chain acyl-CoA synthetase 1 (ACSVL1), an enzyme that is expressed exclusively in the liver and is not found in skeletal muscle, significantly reducing the risk of myotoxicity [18].”
Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics
Zhu, B. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020634 · Cited by 14
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Lipid management to mitigate poorer postkidney transplant outcomes
Skulratanasak, P., & Larpparisuth, N. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000841 · Cited by 10
“3% of placebo), and the initial reduction of estimated glomerular filtration rate; however, this has gradually increased over time [53].”
BackgroundVenkatraman, S., Das, S., Eerike, M., Cherian, J. J., & Bagepally, B. S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03555-8 · Cited by 11
Asbeutah, A. A., Asbeutah, S. A., & Abu-Assi, M. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.058 · Cited by 10
Amore, B. M., Cramer, C. T., MacDougall, D. E., Sasiela, W. J., & Emery, M. G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13116 · Cited by 8
Karla, V. R., Mucherla, R., & Chitta, R. K. (2022) · Chemistry Africa · doi:10.1007/s42250-022-00392-7 · Cited by 11
Bempedoic acid: a novel oral LDL-cholesterol lowering agent.
Jialal, I., & Ramakrishnan, N. (2022) · PubMed · Cited by 13
Current and future options in cholesterol lowering treatments
Elis, A. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.010 · Cited by 12
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O’Donnell, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf219 · Cited by 8
Srivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 8
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 13
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
“After confirming the safety of benzoic acid in 2019 31) , it became available in some countries, and the CLEAR Outcomes trial was presented in the 2023 ACC Annual Scientific Session 30) .”
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.12.002 · Cited by 10
Russo, V., Ratti, G., Parrella, A., De Falco, A., Crisci, M., Franco, R., Covetti, G., Caturano, A., Napolitano, G., Scotto di Uccio, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061839 · Cited by 8
“In a retrospective study [10] including 73 American patients with increased risk for atherosclerotic events and statin intolerance, BA was linked to clinically significant LDL-c reduction (LDL-c −36.7%, −31%, and −20.3% at ≤3, 6, and 12 months, respectively).”
InfluentialIs a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy
Beltran, R. A., Zemeir, K., Kimberling, C. R., Kneer, M. S., Mifflin, M. D., & Broderick, T. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416899 · Cited by 9
Singeisen, H., Renström, F., Laimer, M. W., Lehmann, R., Bilz, S., & Brändle, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad178 · Cited by 8
Uddin, N., Syed, A. A., Ismail, S. M., Ashraf, M. T., Khan, M. K., & Sohail, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102003 · Cited by 8
Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 22
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 16
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials
Agarwala, A., & Goldberg, A. C. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00942-3 · Cited by 8
Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia
Averna, M. R., Bilato, C., & Sesti, G. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.023 · Cited by 8
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 12
Baumann, S., Kettel, L., Stach, K., Özdemir, G. H., Renker, M., Tesche, C., Becher, T., Hetjens, S., Schoepf, U. J., Akın, İ., et al. (2022) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000666 · Cited by 8
Seijas‐Amigo, J., Cordero, A., Olmo, R. F., Quiroga, G. A. C., Fácila, L., Salgado‐Barreira, Á., Reyes-Santías, F., Romero‐Menor, C., Rondán, J., Rodríguez‐Mañero, M., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001365 · Cited by 8
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.